<DOC>
	<DOC>NCT01220180</DOC>
	<brief_summary>This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.</brief_summary>
	<brief_title>Lyrica (Pregabalin) Korean Post Marketing Surveillance Study</brief_title>
	<detailed_description>continuous patients with target disorders in collaborating institutions</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration Nonconsenting Hypersensitivity to the active substance or to any of the excipients galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>fibromyalgia</keyword>
	<keyword>post-market surveillance</keyword>
	<keyword>prospective observational</keyword>
</DOC>